• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TMRW Appoints Brian E. Miller, Ph.D., as SVP of Sales

    3/5/21 9:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    NEW YORK, March 5, 2021 /PRNewswire/ -- TMRW Life Sciences, Inc. ("TMRW"), the creator of the world's first and only automated technology platform for the management, identification, and storage of frozen eggs and embryos, announces today that Brian E. Miller, PhD, is joining TMRW's senior leadership team as Senior Vice President of Sales.

    In his role, Brian will be responsible for bringing TMRW's innovative technology to fertility clinics in the United States. Brian will also be integral to the ongoing development of new products and services that will expand TMRW's offerings, enabling fertility clinics to further enhance and automate their clinical lab operations.

    A veteran of the fertility industry, Brian has over 25 years of experience at the nexus of science and technology, scaling fertility products and solutions and bringing them to market to improve patient care. Brian has an extensive background in biotech and pharma sales, medical affairs, medical practice operations, business development, government affairs, clinical laboratory and research, and alliance partner management. Brian has a profound understanding of the clinicians and patients who he works with, which has allowed him to foster deep and long-lasting relationships with his clients.

    Brian joins TMRW from CooperSurgical, the fertility, genomics, and women's health division of The Cooper Companies (NYSE: COO), where he led all fertility and genomic solutions and patient advocacy for North America.

    Previously, Brian was Chief Commercial Officer at Recombine, a clinical genetic testing company specializing in carrier screening which was acquired by CooperSurgical in 2016. He also served as Chief Operating Officer at the Fertility Centers of New England.  Earlier in his career, Brian held multiple senior positions at EMD Serono, where he helped lead a medical affairs team and managed all U.S. strategic accounts for endocrinology and fertility sales.  At Organon, as a medical liaison, he supported the science and launch of new products through education.

    Brian began his career as an andrologist at the Hospital of Central Connecticut, and advanced to Associate Director of Clinical Research and reproductive endocrinology and andrology lab supervisor. He completed a Ph.D. from the University of Connecticut.

    Alan Murray, TMRW's Founder and Co-CEO commented: "Brian is one of the best known and most respected executives in the fertility field. Over his two decade career, he has won the trust and admiration of the leading clinicians and innovators in not only the fertility space, but also the many key intersecting disciplines such as genetic testing and lab operations. We could not be more delighted by his arrival to further TMRW's appeal to innovators in the fertility space."

    "TMRW is leading the way in developing how IVF will be practiced in the future," said Brian. "The automation revolution TMRW is leading is already benefiting clinicians and patients alike. I'm excited to join a team of innovators, who, in a short period of time, took an extraordinary vision to bring safety to cryospecimen management and developed a game-changing technology solution that will become the community standard in IVF labs worldwide. I am thrilled to be part of the ongoing innovation which is TMRW's future."

    Brian's appointment comes on the heels of TMRW's commercial launch in February 2021.

    About TMRW Life Sciences, Inc.

    TMRW has created the world's first automated platform designed specifically for cryo-management of eggs and embryos used in IVF. TMRW's RFID-enabled, complete digital chain of custody SaaS technology radically improves upon the error-prone manual and analog methods that have gone unchanged throughout the history of IVF, significantly reducing the chances of implantation mix-ups or loss of eggs and embryos. The TMRW team includes many of the world's most celebrated innovators in fertility, embryology, cryo-management, automation, software development and robotics to name a few of the disciplines involved.  TMRW's co-founders, Joshua Abram, Alan Murray, and Dr. Jeffrey Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion. To date, TMRW has raised $50 million. For more information, please visit TMRW.org.

    Media Contact
    Emily Grosser, Dini von Mueffling Communications
    [email protected]
    757-645-5190

    SOURCE TMRW Life Sciences

    Related Links

    https://www.tmrw.org/

    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    2/3/2026$100.00 → $99.00Buy
    Needham
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    10/13/2025$85.00Overweight
    Barclays
    10/1/2025$64.00Sell
    Goldman
    8/28/2025$72.00Buy → Neutral
    Citigroup
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    5/30/2025$76.00Overweight → Neutral
    Analyst
    More analyst ratings

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Cooper with a new price target

    Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously

    2/3/26 7:02:57 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cooper from Overweight to Equal Weight and set a new price target of $72.00

    11/13/25 8:26:09 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Barclays initiated coverage on Cooper with a new price target

    Barclays initiated coverage of Cooper with a rating of Overweight and set a new price target of $85.00

    10/13/25 8:52:29 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    2/3/26 9:58:35 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    The Cooper Companies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    12/23/25 5:04:27 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    12/12/25 4:42:03 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperVision Launches MiSight® 1 day in Japan; Becomes First Myopia Control Contact Lens in Leading Vision Care Market

    CooperVision Strengthens Global Footprint with Expanded Access to Myopia Management in Asia-Pacific ROCHESTER, N.Y., Feb. 10, 2026 /PRNewswire/ -- CooperVision today announced immediate availability of its MiSight® 1 day* myopia control contact lens in Japan, where as many as 77% of elementary school children are estimated to be myopic, equating to millions who could benefit from myopia control treatments.1 The country represents approximately 12% of the global contact lens marketplace.2 MiSight® 1 day is the first soft contact lens authorized by Japan's Ministry of Health, La

    2/10/26 7:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperVision Partners with Canadian Sprint Canoe Athlete Nikita Ciudin on His Journey to Compete on the World Stage

    RICHMOND HILL, ON, Jan. 7, 2026 /CNW/ - CooperVision Canada is proud to announce its sponsorship and partnership with Nikita Ciudin, an elite sprint canoe paddler and dedicated MiSight® 1 day contact lens wearer, as he strives toward representing Team Canada at the world's biggest sporting event. Nikita's story is one of vision—both literal and figurative. Diagnosed with myopia at a young age, Nikita has relied on MiSight® 1 day* contact lenses to slow the worsening of his myopia1 while pursuing his passion for competitive paddling. Today, he is a rising star in Canadian sprin

    1/7/26 5:16:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by EVP, CFO & Treasurer Andrews Brian G

    4/A - COOPER COMPANIES, INC. (0000711404) (Issuer)

    2/13/26 4:38:35 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form 4 filed by President & CEO White Albert G Iii

    4/A - COOPER COMPANIES, INC. (0000711404) (Issuer)

    2/13/26 4:38:15 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Jay Colleen exercised 7,064 shares at a strike of $39.40, increasing direct ownership by 24% to 36,585 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    1/14/26 4:05:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

    SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GAAP diluted EPS of $1.15, up 11%. Fiscal 2025 non-GAAP diluted EPS of $4.13, up 12%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We closed fis

    12/4/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025

    SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience l

    11/4/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care